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The aim of this study was to determine optimal cutoff scores for the Hospital Anxiety and Depression Scale (HADS) when used in
evaluating cancer patients in acute care. A total of 689 cancer patients were assessed during their first days of in-patient treatment,
using the structured clinical interview for DSM and the HADS. Statistical analysis was performed using ROC curves. A total of 222
patients (32%) had a mental disorder. The area under the curve was the best in the total scale of the HADS, namely 0.73. With a
score of X13, it is possible to detect 76% of the cases with a specificity of .60, whereas 95% of the cases can be detected with a score
of X6 (specificity 0.21). With scores of X16 and X22, recommended by the test authors for primary care, only 59 and 30% of the
comorbid cancer patients are indicated. Lower HADS cutoff scores when preferable when evaluating cancer patients than are
recommended for use in primary care. When using HADS in clinical practice and epidemiological studies, it is important to decide
whether, for the task at hand, high detection rates of affected patients or low misclassification rates are more important.
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As cancer is a potentially life-threatening disease, usually involving
relatively aggressive and intrusive treatment, it presents a
challenge for the patients’ psychological adjustment and ability
to cope. Comprehensive care, therefore, includes not only medical
procedures but also mental health care. As a prerequisite, it is
important to identify patients who are mentally affected and need
further support and/or treatment.
On the one hand, it is known that a third of all cancer
patients receiving oncological treatment, and half of the patients
who have advanced cancer, suffer from mental distress, to an
extent that they can be diagnosed with a psychiatric disorder
(Derogatis et al, 1983; Ha ¨rter et al, 2000; Atesci et al, 2004; Miovic
and Block, 2007; Singer et al, 2007; Walker et al, 2007). On the
other hand, physicians and nurses often fail to identify distressed
patients (Newell et al, 1998; Fallowfield et al, 2001; So ¨llner et al,
2001; Keller et al, 2004), resulting in under-treatment in 40–90%
of the cases (Flatten et al, 2003; Singer et al, 2005). It is,
nevertheless, possible to improve the detection rates and treatment
with intensive training (Passik et al, 2002; Adkins et al, 2005).
Feedback of patients’ self-reported psychosocial well-being
to the oncologist alone did not, however, reduce the levels of
anxiety and depression in a randomised controlled trial (Boyes
et al, 2006).
Therefore, questionnaires screening for psychological comor-
bidity and cooperation with mental health care professionals
are the most usual way to improve detection rates and patient
care. Several indices have been developed and validated so far,
and the debate regarding the question of which tool is the most
suitable for the purpose is ongoing (Kirsh et al, 2004; Herschbach,
2006).
In oncological contexts, the HADS is one of the most commonly
used questionnaires for identifying distress (Zigmond and Snaith,
1983). This is a 14-item questionnaire with cutoff points indicating
‘cases’ helping oncologists to decide whether or not a mental
health care professional should be integrated in the treatment of a
patient – an advantage in day-to-day care.
Each item of the HADS has a Likert response scale. Scores are
constructed by summation, whereby increasing scores indicate
increasing burden. There are two subscales: depression (HADS-D)
and anxiety (HADS-A).
The optimal cutoff point is said to be X8 for the identification
of suspicious cases and X11 for safe cases on both subscales
(Zigmond and Snaith, 1983; Bjelland et al, 2002), with a sensitivity
and specificity of 0.80 on an average (Bjelland et al, 2002). These
scores, however, were conceived for evaluating primary care
patients. It has been shown (Morse et al, 2005) that these
thresholds might be too high for cancer patients, resulting in
underrecognition of ‘cases’. Therefore, lower thresholds may be
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srequired without necessarily compromising specificity. In addi-
tion, it would be easier to handle one score instead of two in
clinical routine; therefore, we wanted to test the performance of the
HADS total scale with regard to specificity and sensitivity.
However, what is an optimal cutoff point? Some authors prefer a
score that (a) gives the best proportion of sensitivity and
specificity, indicating the point at which the percentage of wrongly
classified patients is reduced to a minimum (‘balanced score’).
However if, as should be the case in day-to-day care, it is deemed
less desirable for a patient with problems to go undiagnosed and in
continued need of psychosocial help than it is for a psycho-
oncologist to be called ‘unnecessarily’ to talk with a mentally
healthy patient, we need another score termed the (b) ‘clinical
score’, defined as being a point at which at least 95% of cases are
identified. For research purposes, it can also be interesting to
define another score called the (c) ‘specific score’, whereby
specificity is 0.95, indicating that 95% of the identified cases are
true cases. With this study, we tried to find these three cutoff
scores for a large number of cancer in-patients and compare them
to the scores suggested by the authors of the HADS.
STUDY DESIGN AND PROCEDURE
We conducted a multicentre cross-sectional study with consecutive
patient accrual. Study clinics were clinics of the University of
Leipzig (Department of Surgery II, Department of Obstetrics and
Gynaecology, Department of Urology and Department of Radio-
therapy) and Leipzig’s St Georg Hospital’s Department of
Obstetrics and Gynaecology.
Inclusion criteria were cancer diagnosis, age 18 or above, ability
to speak and understand German, ability to complete a
questionnaire and informed consent.
All in-patients diagnosed or treated for cancer between
September 2002 and June 2004 in the participating clinics were
contacted.
Eligible patients were approached by a research assistant who
explained the study and requested their consent to participate.
Before seeing a psychologist, the consenting patients completed
the HADS. At day 2 or 3 after their admission to the hospital, a
structured interview was conducted by a psychologist, who was
blinded to the patients’ HADS scores.
The Structured Clinical Interview for DSM-IV (SCID), German
Version (First et al, 1997; Jacobi et al, 2004) was conducted to act
as a gold standard for identifying cases. It identifies a broad range
of psychiatric disorders according to the Diagnostic Statistical
Manual of Psychological Illnesses, Version 4. Beginning with
screening questions, such as ‘Have you felt nervous or anxious in
the last 6 months?’, the interviewer, suspecting the presence of a
psychiatric disorder, continues by asking questions regarding the
frequency of symptom occurrence, the extent of suffering caused
by the symptoms and the general health of the patient, taking into
account the possibility that the symptoms could be the results of
other conditions, such as an organic illness. The study was
approved by the local Ethics Committee of the University of
Leipzig.
Sample
A total of 2913 cancer patients were treated in the study clinics
during the investigation period. In all, 62 (2.1%) of them could not
be contacted due to early discharge or death. A total of 528 (18.1%)
patients did not fulfil the inclusion criteria, resulting in 2323
remaining eligible patients. In all, 518 (38.0%) of them refused
participation; 1805 (62%) patients took part in the study; and 1526
(84.5% of the study participants) were seen during the first few
days following their admission to the hospital and completed the
HADS questionnaire at that time. In 689 cases, a diagnostic
interview was possible. Reasons for non-participation in the SCID
were merely that people wanted to rest or that it was not possible
to conduct the interview because of organisational problems, such
as the patient being absent because of diagnostics or treatment.
The resulting 689 data sets create the basis for the following
analyses.
Statistical analyses
Demographic and clinical characteristics of participating and non-
participating patients were compared using w
2-tests for categorical
data and the independent sample t-test for continuous data.
The screening ability of the HADS total and subscale scores to
discriminate between cases and non-cases at a range of cutoff
points was assessed using receiver operating characteristic (ROC)
curves. The area under the ROC curve (AUC) indicates overall
performance, with a greater AUC reflecting better performance.
The sensitivity, specificity and positive and negative predictive
values (PPV and NPV) were calculated at all possible cutoff points
for the HADS total and subscale scores. Sensitivity refers to the
proportion of correctly identified cases and specificity to the
proportion of correctly identified non-cases. Predictive value is the
probability that patients identified by the HADS are cases
according to the SCID; NPV refers to the proportion of true
non-cases to all negative test results.
A first cutoff point (‘balanced score’) was defined so as to
optimise the proportion of sensitivity and specificity scores. This
proportion was calculated according to the formula (sensitivityþ
specificity)/2.
A second cutoff point (‘clinical score’) was set at the scores with
0.95 sensitivity, indicating a test result at which 95% of the true
cases are identified by the screening instrument.
Finally, a ‘specific score’ was defined as the point at which 95%
of the identified cases are true cases (¼specificity 0.95 or higher).
All analyses were performed using SPSS for Windows.
RESULTS
Sample characteristics
The characteristics of the study sample are displayed in Table 1.
Participants who completed the SCID interview were comparable
with those who did not (patients who participated in the study but
were not able or willing to be interviewed) on the basis of age,
tumour stage, time since diagnosis, marital status and mental well
being (HADS scores). There were, however, more male SCID-
participants than females (Po0.01).
Psychiatric morbidity
According to the DSM-IV, 222 (32.2%) of the patients had a mental
disorder. A total of 142 cancer patients (20.6%) had one, and 80
patients (11.6%) had two or more psychiatric disorders. The most
frequent mental disorder was depression, with a rate of 11.6%
(major depression 9.6%, dysthymia 2.0%). Of the patients studied,
6.8% had adjustment disorders, 6.4% specific phobia, 5.7%
generalised anxiety disorders, 5.1% alcohol dependencies, 4.2%
posttraumatic stress diseases, 3.6% (legal) drug dependencies,
1.5% (illegal) drug dependencies, 3.0% acute stress reactions, 2.9%
panic disorders and 0.6% social phobia. A total of 10.4% of the
patients were screened for somatisation.
In the following analyses, we deliberately did not differentiate
between the different disorders. Our reasoning for this is that it is
important in clinical routine to screen for every kind of mental
distress and to call a psychologist to do further diagnostics and/or
intervention if the screening indicates any type of disorder.
Patients with gynaecological, head and neck, urological (not
prostate) and lung tumours were more affected than others, with a
HADS cutoff scores
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sprevalence of 43.9, 41.3, 41.1 and 40.0% , respectively. The average
HADS scores were 7.2 (s.d.: 4.2), 6.4 (s.d.: 4.5) and 13.6 (s.d.: 7.8)
for the anxiety, depression and total scales, respectively.
Optimal cutoff points
The areas under the curve were 0.698 (HADS-D), 0.711 (HADS-A)
and 0.726 (HADS-T) indicating a good performance of the HADS,
especially the total score (see Table 2). All scales were significantly
related to the gold standard criterion (all P-values o0.001).
Figure 1 shows the ROC curves.
Different cutoff scores can be found in Table 3. The best
trade between sensitivity and specificity is X5 (HADS-D), X7
(HADS-A) and X13 (HADS-T). For clinical purposes, the follow-
ing optimal thresholds were found: X2 (HADS-D), X3 (HADS-A)
and X6 (HADS-T).
DISCUSSION
Cancer is a threatening disease, often accompanied by difficult
losses (of organ functions, social roles, physical strength, and
so on), resulting in severe mental distress in a substantial number
of patients (Keller et al, 2004; Singer et al, 2007). In an ideal world,
every patient could see a psycho-oncologist. In reality, however,
the financial resources are not there to support such an endeavour.
As a result, all cancer patients should be triaged using screening
instruments.
With this study, we aimed to identify optimal cutoff scores for
one of the most commonly used screening tools for mental distress
in oncology, the HADS.
As suggested by Morse et al (2005), lower thresholds should be
used for cancer patients. The best trade between sensitivity and
specificity for the total scale was a X13 score, for example, instead
of the X16 score recommended by Zigmond and Snaith (1983).
What we need to think about now is what the optimal cutoff
point should be for everyday clinical use. One could say that the
combined level of sensitivity and specificity should be as high as
possible. This would be a technical solution, potentially useful in
large epidemiological studies in which it is not possible to ‘refine’
diagnostic procedures for patients with high scores, for instance,
when clinical interviews are not being used. In caring for cancer
patients, however, we need – in our view – other criteria. For
example, it should be judged as suboptimal practice if depression
in a patient who could be helped by talking with a psychotherapist
or by receiving antidepressants goes undetected by the HADS
Table 2 Areas under the curve of the HADS subscales and total score
Asymptotic 95% confidence interval
Area s.e. Asymptotic significance Lower bound Upper bound
HADS depression 0.698 0.023 o0.001 0.654 0.743
HADS anxiety 0.711 0.023 o0.001 0.666 0.755
HADS total score 0.726 0.022 o0.001 0.683 0.769
1.0 0.8 0.6 0.4 0.2 0.0
1 - Specificity
1.0
0.8
0.6
0.4
0.2
0.0
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HADS-A
HADS-D
HADS-T
Source of the curve
Figure 1 ROC curve of HADS-T, HADS-D and HADS-A. Gold
standard: SCID.
Table 1 Sample characteristics
N%
Sex
Male 404 58.6
Female 285 41.4
Age
o30 13 1.9
30–39 34 4.9
40–49 101 14.7
50–59 159 23.1
60–69 239 34.7
70–79 125 18.1
X80 18 2.6
Treatment
Surgery 395 57.3
Chemotherapy 28 4.1
Radiotherapy 118 17.1
Radiochemotherapy 103 14.9
Diagnostics 31 4.5
Other 14 2
Tumour stage (UICC)
0 13 1.9
I 122 17.7
II 148 21.5
III 124 18
IV 71 10.3
Not yet known 211 30.6
Tumour localisation
Breast 76 11
Gynaecological tumours 98 14.2
Prostate 119 17.3
Other urological tumours 90 13.1
Lung 25 3.6
Colon 30 4.4
Other gastrointestinal tumours 134 19.4
Head and neck 46 6.7
Brain 35 5.1
Other 36 5.2
HADS cutoff scores
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sand/or medical staff (depressed patients are often not identified by
physicians) and remains untreated as a result. Therefore, the
threshold of the HADS must be lowered. Of course, taking this
approach means that specificity becomes worse, resulting in
psycho-oncologists having to talk with ‘non-cases’ more often. But,
is the impact of that ‘error’ comparable with the first one? We
think it is not, and we would welcome a debate on this issue. We
would like to argue that interaction with a patient is never a ‘waste
of time’. The interaction may be brief and the patient may opt to
act on an ‘offer of services’ several months or years later. One of
the participants in our study wrote on the questionnaire: ‘It’s good
to know that I can have some support. I do not need it now but I
would like to keep this option open. I might call you later.’ This is a
good example for what we call prevention.
There are several limitations of our investigation that we would
like to mention. First of all, it was only possible to clinically
interview a portion of the patients. This was mainly due to
organisational problems, but it could have resulted in a biased
sample, representing only patients with few psychological pro-
blems. As, however, the prevalence rate of psychiatric disorders is
comparable to similar studies (Keller et al, 2004), and the HADS-
scores of participants and non-participants are equal, we can
assume that this is not the case.
Secondly, we have to think about the timing of the administra-
tion of the HADS. In our study, the participants completed the
questionnaire and the SCID soon after the admission to the
hospital. It may be useful to readminister it later on. A subsample
of the patients (n¼389) in this study completed the HADS a
second time before discharge from the hospital and, on an average,
the mean score did indeed decrease over time (13.1 at admission,
11.1 at discharge; paired t-test (t¼6.51, Po0.001)). However, we
do not have a second SCID of all the patients and therefore cannot
perform a second ROC analysis.
Nonetheless, it is more important in our view to triage the
patients at the beginning of their stay in the hospital, as this is the
time of the highest distress and the greatest need for support.
Another limitation is that we did not compare different
screening tools, something that would have been interesting to
do. Other instruments include questions regarding the need for
additional information about cancer diagnosis and treatment
(Herschbach et al, 2004; Arraras et al, 2007). The HADS is able to
screen mental distress, but we cannot conclude from our data that
it is sufficient for identifying the need for psychosocial support.
This need not only depends on psychological comorbidity, but also
on poor social support, and the patients’ desire for such support as
well (So ¨llner et al, 2001). However, knowledge and awareness of
patients’ level of distress is an important issue in clinical care, and
the use of the HADS screening instrument can be helpful in
identifying comorbid patients.
Our recommendation for clinical purposes, derived from the
study results, is to use the total scale of the HADS, because it has
the best AUC parameters, and it is easier to handle one scale than
two. If one wants to minimise misclassifications, every patient who
scores X13 should be referred to a psycho-oncologist. In our
dataset, 51% of all patients fulfilled that criterion. If one prefers to
identify nearly all cancer patients with a mental disorder, the cutoff
point should be set at X6. In this study, 84% of all cancer patients
had HADS scores according to that criterion. As a consequence,
psycho-oncological services at many hospitals providing cancer
treatment may need more financial resources than they currently
have. Using a screening instrument on the other hand might, by
triaging all cancer patients, help in allocating financial resources
more precisely and, therefore, more adequately.
We would welcome the day when, as part of standard care, all
cancer patients receive a psychosocial screening instrument, the
results of which would be perused by the appropriate clinician, just
as currently a standard serum test is quickly reviewed for
abnormalities. In fact, this is already being done in some places
and seems to work well (Sellick and Edwardson, 2007). Some
clinicians might worry that patients may be bothered by there
being so many questions to answer (14). We asked the participants
at the end of the survey to openly express their opinion about the
questionnaire. Most of the patients said they were thankful for the
opportunity to answer the questions. Some patients, for example,
said: ‘Thank you for this questionnaire. It helped me to think
about myself and to organise my thoughts.’and ‘It was good to be
able to talk about this without time pressure.’ Only two patients
thought that the questionnaire was too long. Some said they would
like to be examined a second time, as their cancer diagnosis was
not clear yet, for example: ‘It is difficult to answer. The results of
my surgery are still unclear.’ Some even articulated a wish for more
in-depth conversation: ‘The results can mislead you as my feelings
Table 3 Cutoff scores of the HADS subscales and total score
Score Sensitivity Specificity (Sensitivity+specificity)/2 PPV NPV
HADS Depression
Clinical X2 0.95 0.21 0.58 0.35 0.89
Regular ZS X8 0.55 0.75 0.65 0.50 0.78
Balanced X5 0.82 0.49 0.65 0.42 0.85
Specific ZS X11 0.30 0.88 0.59 0.53 0.73
Specific X15 0.10 0.96 0.53 0.51 0.70
HADS anxiety
Clinical X3 0.95 0.18 0.56 0.35 0.88
Regular ZS X8 0.67 0.67 0.66 0.48 0.82
Balanced X7 0.75 0.56 0.67 0.44 0.83
Specific ZS X11 0.37 0.86 0.62 0.55 0.75
Specific X15 0.11 0.95 0.53 0.53 0.70
HADS total score
Clinical X6 0.96 0.21 0.59 0.36 0.91
Regular ZS X16 0.59 0.76 0.67 0.53 0.80
Balanced X13 0.76 0.60 0.68 0.47 0.84
Specific ZS X22 0.30 0.89 0.59 0.54 0.73
Specific X27 0.14 0.95 0.55 0.57 0.71
Balanced¼best trade between sensitivity and specificity; Clinical¼recommended score for clinical purposes, that is, sensitivity min 0.95; Regular ZS¼optimal score in identifying
suspicious cases according to Zigmond and Snaith; Specific¼specificity min 0.95; Specific ZS¼optimal score in identifying safe cases according to Zigmond and Snaith;
NPV¼negative predictive value; PPV¼positive predictive value.
HADS cutoff scores
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sand my ‘life’ can not be squeezed into a matrix. I often had to add
explanations as my ‘cross’ actually belonged somewhere in
between the given marks.’ This last point raises again the question
of how a screening instrument should best be administered and
interpreted. On the basis of our clinical experiences and the
responses of the participants, we think that the HADS should be
handed out personally and used as a tool in the hands of
experienced psychosocial clinicians.
ACKNOWLEDGEMENTS
We are particularly grateful to all of the patients who participated
in the investigation. Thanks are also extended to the collaborating
study clinics. This project was financed with a grant from the
German Federal Ministry for Education and Research (no.
01ZZ0106). We also thank two anonymous reviewers for their
helpful comments on the first version of the manuscript.
REFERENCES
Adkins B, Titus-Howard T, Massey V, Washburn N, Molinaro J, Lang B,
Bruning WL, Simmons S, Gerken P, Sommer V, LaNoue K, Rogers B,
Wilson B (2005) Recognizing depression in cancer outpatients. Commu-
nity Oncol 2: 528–533
Arraras JI, Kuljanic-Vlasic K, Bjordal K, Yun YH, Efficace F, Holzner B,
Mills J, Greimel E, Krauss O, Velikova G (2007) EORTC QLQ-INFO26: a
questionnaire to assess information given to cancer patients – a
preliminary analysis in eight countries. Psycho-Oncol 16: 249–254
Atesci FC, Baltalarli B, Oguzhanoglu NK, Karadag F, Ozdel O, Karagoz N
(2004) Psychiatric morbidity among cancer patients and awareness of
illness. Support Care Cancer 12: 161–167
Bjelland I, Dahl AA, Haug TT, Neckelmann D (2002) The validity of the
hospital anxiety and depression scale: an updated literature review.
J Psychosom Res 52: 69–77
Boyes A, Newell S, Girgis A, McElduff P, Sanson-Fisher R (2006) Does
routine assessment and real-time feedback improve cancer patients’
psychosocial well-being? Eur J Cancer Care 15: 163–171
Derogatis LR, Morrow GR, Fetting J (1983) The prevalence of psychiatric
disorders among cancer patients. JAMA 249: 751–757
Fallowfield L, Ratcliffe D, Jenkins V, Saul J (2001) Psychiatric morbidity
and its recognition by doctors in patients with cancer. BJC 84: 1011–1015
First M, Spitzer R, Gibbon M, Williams J (1997) Structured Clinical
Interview for DSM-IV Axis I Disorders (SCID-I), Clinician Version.
American Psychiatric Press: Washington, DC
Flatten G, Ju ¨nger S, Gunkel S, Singh J, Petzold E (2003) Traumatic and
psychosocial distress in patients with acute tumors. Psychotherapie
Psychosomatik Medizinische Psychologie 53: 191–201
Ha ¨rter M, Reuter K, Schretzmann B, Hasenburg A, Aschenbrenner A, Weis
J (2000) Comorbid mental disorders in cancer patients in acute care and
rehabilitation treatment. Rehabilitation 39: 317–323
Herschbach P (2006) The need for treatment in psychooncology. Principles
and assessment strategies. Onkologe 12: 41–47
Herschbach P, Keller M, Knight L, Brandl T, Huber B, Henrich G, Marten-
Mittag B (2004) Psychological problems of cancer patients: a cancer
distress screening with a cancer-specific questionnaire. BJC 91: 504–511
Jacobi F, Wittchen H-U, Ho ¨lting C, Ho ¨fler M, Pfister H, Mu ¨ller N, Lieb R
(2004) Prevalence, co-morbidity and correlates of mental disorders in the
general population: results from the German Health Interview and
Examination Survey (GHS). Psychol Med 34: 1–15
Keller M, Sommerfeldt S, Fischer C, Knight L, Riesbeck M, Lowe B,
Herfarth C, Lehnert T (2004) Recognition of distress and psychiatric
morbidity in cancer patients: a multi-method approach. Ann Oncol 15:
1243–1249
Kirsh KL, McGrew JH, Dugan M, Passik SD (2004) Difficulties in screening
for adjustment disorder, Part I: Use of existing screening instruments in
cancer patients undergoing bone marrow transplantation. Palliat Suppor
Care 2: 23–31
Miovic M, Block S (2007) Psychiatric disorders in advanced cancer. Cancer
110: 1665–1676
Morse R, Kendell K, Barton S (2005) Screening for depression in people
with cancer: the accuracy of the hospital anxiety and depression scale.
Clin Eff Nurs 9: 188–196
Newell S, Sanson-Fisher RW, Girgis A, Bonaventura A (1998) How well do
medical oncologists’ perceptions reflect their patients’ reported physical
and psychosocial problems?Data from a survey of five oncologists.
Cancer 83: 1640–1651
Passik SD, Kirsh KL, Theobald D, Donaghy K, Holtsclaw E, Edgerton S,
Dugan W (2002) Use of a depression screening tool and a fluoxetine-
based algorithm to improve the recognition and treatment of depression
in cancer patients: a demonstration project. J Pain Symptom Manage 24:
318–327
Sellick SM, Edwardson AD (2007) Screening new cancer patients for
psychological distress using the hospital anxiety and depression scale.
Psychooncology 16: 534–542
Singer S, Bringmann H, Hauss J, Kortmann R-D, Ko ¨hler U, Krauß O,
Schwarz R (2007) Ha ¨ufigkeit psychischer Begleiterkrankungen und
der Wunsch nach psychosozialer Unterstu ¨tzung bei Tumorpatienten
im Akutkrankenhaus. Deutsche Medizinische Wochenschrift 132:
2071–2076
Singer S, Herrmann E, Welzel C, Klemm E, Heim M, Schwarz R
(2005) Comorbid mental disorders in laryngectomees. Onkologie 28:
631–636
So ¨llner W, DeVries A, Steixner E, Lukas P, Sprinzl G, Rumpold G,
Maislinger S (2001) How successful are oncologists in identifying patient
distress, perceived social support, and need for psychosocial counselling?
BJC 84: 179–185
Walker J, Postma K, McHugh GS, Rush R, Coyle B, Strong V (2007)
Performance of the hospital anxiety and depression scale as a screening
tool for major depressive disorder in cancer patients. J Psychosom Res 63:
83–91
Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale.
Acta Psychiatr Scand 67: 361–370
HADS cutoff scores
S Singer et al
912
British Journal of Cancer (2009) 100(6), 908–912 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s